ClinicalTrials.gg
CompletedNCT06194032Updated Apr 25, 2025

A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants

A Phase 1 interventional study of Baxdrostat and Placebo in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-25.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2024, 2 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will assess the effect of single oral doses of baxdrostat on the ECG interval measured from the onset of the QRS complex to the end of the T wave (QT) interval corrected for HR using Fridericia's formula (QTcF) compared to placebo using a concentration-QTcF analysis, and with moxifloxacin as positive control, in healthy participants.

Read the detailed description

This is a randomised, placebo-controlled, double-blind, 4-way crossover TQT study to assess the effect of single oral doses of baxdrostat on the QTcF compared to placebo using a concentration-QTcF analysis, and with open-label moxifloxacin as positive control, in 28 healthy participants, performed at a single clinical unit.

The study will comprise of:

  • a screening period of maximum 28 days,
  • four treatment periods during which participants will be resident at the Clinical Unit from Treatment Period Day -1 until at least 48 hours after dosing (Treatment Period Day 3).
  • a final Follow-up Visit within 7 to 10 days following discharge after Visit 5

Participants will each receive a single dose of all treatments in a cross-over design over 4 treatment periods. Participants will be randomised to 1 of 4 treatment sequences with equal allocation regarded as a Williams design of order 4.

Treatment Periods will be separated by a washout period of at least 7 days but no more than 9 days.

02

Conditions studied

  • Healthy Participants

Keywords

  • Aldosterone synthase inhibitor
  • QT/QTc interval
  • Moxifloxacin
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females must have a negative pregnancy test.
  • Have a Basal Metabolic index () between 19 and 30 kg/m2 inclusive and weigh at least 50 kg.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder.
  • History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • History of additional risk factors for Torsade de Pointes.
  • History of neoplastic disease.
  • Family history of sudden cardiac death.
  • Any skin condition likely to interfere with electrode placement or adhesion.
  • Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of drug.
  • Any clinically significant abnormalities at screening and first admission in rhythm, conduction, or morphology of the 12-lead resting ECG and any clinically important abnormalities in the 12-lead ECG as considered by the investigator.
  • Participant has clinical signs and symptoms consistent with COVID-19.
  • Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 3 months prior to screening.
  • Positive screen for drugs of abuse, alcohol or cotinine at screening or on each admission to the Clinical Unit.
  • Participants who have previously received Baxdrostat.
  • Participants with any special dietary restrictions such as participants who are lactose intolerant or are vegetarians/vegans.
  • Participants who cannot communicate reliably with the investigator and/or are not able to read, speak, and understand the local language.
  • Vulnerable participants, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Treatment Sequence ABCD

    Dummy sequence according to CSP: Participants will receive a single dose of all 4 treatments (ABCD) in a crossover design with a washout period of at least 7 days between each study dose administration.

    Drug: Baxdrostat · Drug: Placebo · Drug: Moxifloxacin

  • Experimental
    Treatment Sequence BDAC

    Dummy sequence according to CSP: Participants will receive a single dose of all 4 treatments (BDAC) in a crossover design with a washout period of at least 7 days between each study dose administration.

    Drug: Baxdrostat · Drug: Placebo · Drug: Moxifloxacin

  • Experimental
    Treatment Sequence CADB

    Dummy sequence according to CSP: Participants will receive a single dose of all 4 treatments (CADB) in a crossover design with a washout period of at least 7 days between each study dose administration.

    Drug: Baxdrostat · Drug: Placebo · Drug: Moxifloxacin

  • Experimental
    Treatment Sequence DCBA

    Dummy sequence according to CSP: Participants will receive a single dose of all 4 treatments (DCBA) in a crossover design with a washout period of at least 7 days between each study dose administration.

    Drug: Baxdrostat · Drug: Placebo · Drug: Moxifloxacin

Interventions

  • Participants will receive baxdrostat as two separate doses.

  • DrugPlacebo

    Participants will receive baxdrostat matching placebo.

  • Participants will receive a single dose moxifloxacin

06

What researchers measure

Primary outcomes

  1. Placebo corrected change from baseline in QTcF (ΔΔQTcF)

    The effect of single doses of baxdrostat on QTcF compared to placebo using a concentration-QTcF analysis will be assessed.

    Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

Secondary outcomes

  1. Heart Rate (HR)

    The effect of baxdrostat on HR will be assessed.

    Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

  2. RR interval

    The effect of baxdrostat on RR interval will be assessed.

    Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

  3. PR interval

    The effect of baxdrostat on PR interval will be assessed.

    Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

  4. QRS interval

    The effect of baxdrostat on QRS interval will be assessed.

    Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

  5. Change from baseline in Heart rate (ΔHR)

    The effect of baxdrostat on HR will be assessed.

    Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

  6. QT interval

    The effect of baxdrostat on QT interval will be assessed.

    Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

  7. Change from baseline in RR interval (ΔRR)

    The effect of baxdrostat on ΔRR interval will be assessed.

    Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

  8. Change from baseline in PR interval (ΔPR)

    The effect of baxdrostat on ΔPR interval will be assessed.

    Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

  9. Change from baseline in QRS interval (ΔQRS)

    The effect of baxdrostat on ΔQRS interval will be assessed.

    Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

  10. Change from baseline in QTcF (ΔQTcF)

    The effect of baxdrostat on ΔQTcF will be assessed.

    Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

  11. Change from baseline in QT interval (ΔQT)

    The effect of baxdrostat on ΔQT interval will be assessed.

    Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

  12. Number of participants with significant change in QTcF

    The presence of categorical outliers for QTcF after baxdrostat administration will be assessed.

    Time frame: Day 1 to Day 3

  13. Number of participants with significant change in PR interval

    The presence of categorical outliers for PR interval after baxdrostat administration will be assessed.

    Time frame: Day 1 to Day 3

  14. Number of participants with significant change in QRS interval

    The presence of categorical outliers for QRS interval after baxdrostat administration will be assessed.

    Time frame: Day 1 to Day 3

  15. Number of participants with significant change in RR interval

    The presence of categorical outliers for RR interval after baxdrostat administration will be assessed.

    Time frame: Day 1 to Day 3

  16. Number of participants with significant change in QT interval

    The presence of categorical outliers for QT interval after baxdrostat administration will be assessed.

    Time frame: Day 1 to Day 3

  17. Number of participants with significant change in HR

    The presence of categorical outliers for HR after baxdrostat administration will be assessed.

    Time frame: Day 1 to Day 3

  18. Placebo corrected change from baseline in HR (ΔΔHR)

    The effect of baxdrostat on ΔΔHR will be assessed.

    Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

  19. Placebo corrected change from baseline in RR interval (ΔΔRR)

    The effect of baxdrostat on ΔΔRR interval will be assessed.

    Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

  20. Placebo corrected change from baseline in PR interval (ΔΔPR)

    The effect of baxdrostat on ΔΔPR interval will be assessed.

    Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

  21. Placebo corrected change from baseline in QRS (ΔΔQRS)

    The effect of baxdrostat on ΔΔQRS interval will be assessed.

    Time frame: Visit 2,3, 4 and 5:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

  22. AUClast of Baxdrostat

    The PK of baxdrostat will be assessed.

    Time frame: Day 1 to Day 3

  23. AUCinf of Baxdrostat

    The PK of baxdrostat will be assessed.

    Time frame: Day 1 to Day 3

  24. Maximum observed plasma peak concentration (Cmax) of baxdrostat

    The PK of baxdrostat will be assessed.

    Time frame: Day 1 to Day 3

  25. Time to reach peak or maximum observed concentration (Tmax) of baxdrostat

    The PK of baxdrostat will be assessed.

    Time frame: Day 1 to Day 3

  26. Number of participants with Adverse Events (AEs)

    The safety and tolerability of baxdrostat will be assessed.

    Time frame: Day 1 to last day of follow-up (approximately 7 to 10 days after the last dose)

  27. Number of participants with Adverse events of special interest

    The safety and tolerability of baxdrostat will be assessed. For this clinical study, AESIs include the following: hyperkalaemia, hyponatraemia, and hypotension events that require intervention.

    Time frame: Day 1 to last day of follow-up (approximately 7 to 10 days after the last dose)

  28. Number of treatment-emergent changes in T-wave morphology

    Morphological changes in the T-wave after baxdrostat administration will be assessed.

    Time frame: Day 1 to Day 3

  29. Number of treatment-emergent changes in U-waves presence and morphology

    Morphological changes in the U wave after baxdrostat administration will be assessed.

    Time frame: Day 1 to Day 3

07

Study locations

1 site
  • Research Site
    Berlin, 14050, Germany
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in May 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2023
First posted
Jan 8, 2024
StartActual
Feb 29, 2024
Primary completionActual
May 13, 2024
CompletionActual
May 13, 2024
Last update
Apr 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06194032
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 8, 2024
Start date
Feb 29, 2024
Primary completion
May 13, 2024
Completion
May 13, 2024
Last update
Apr 25, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Baxdrostat · Moxifloxacin

Start the discussion